Participant may take ibrutinib for up to 2 years (24 cycles). If at the end of 2 years participant is benefitting from ibrutinib and the study doctor thinks it is in participant's best interest to continue taking it, other treatment options will be discussed with participant to allow participant to continue to take ibrutinib.